Interestingly, Zhang et al. (2017) identified ERP29 (endoplasmic reticulum protein 29) as a key mediator of chemoresistance by the aggregation prone R282W mutp53 and suggest that targeting ERP29 may sensitize cancer cells to cisplatin treatment. Here, ERP29 is linked to cancer.